Vismodegib (Erivedge®)

Assessment Status Assessment process complete
Drug Vismodegib
Brand Erivedge®
Indication For the treatment of adult patients with locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy or metastatic basal cell carcinoma.
Assessment Process
Rapid review commissioned 02/05/2013
Rapid review completed 20/05/2013
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 16/09/2013
NCPE assessment completed 21/01/2014
NCPE assessment outcome Reimbursement not recommended

Technical Summary

The HSE has approved reimbursement following confidential price negotiations October 2017.